Therefore, the differential binding of KLF14 and EGR2 and expression of downstream EPHA4 impact both tumor growth and drug sensitivity, suggesting that chromatin remodeling in different PDMC may interfere with their ability to predict therapeutic outcomes. The gene discussed is EGR2; the disease is neoplasm.